Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients

Saeedeh Mousavi; Leila Kohan; Majid Yavarian; Asadollah Habib

Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients

Mol Biol Res Commun. 2017 Jun;6(2):91-94.

Authors

Saeedeh Mousavi¹, Leila Kohan^{1

2}, Majid Yavarian³, Asadollah Habib⁴

Affiliations

¹ Department of Biology, Arsanjan branch, Islamic Azad University, Arsanjan, Iran.
² Yong researchers and elite club, Islamic Azad University, Arsanjan Branch, Arsanjan, Iran.
³ Shiraz Nephro-Urology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
⁴ Department of Endocrinology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

PMID: 28775995
PMCID: PMC5534524

Abstract

Type 2 diabetes mellitus is a worldwide epidemic disorder with considerable health and economic consequences. Metformin is one of the most commonly prescribed oral antidiabetic drugs. Pharmacogenetic studies showed that variants in genes related to the pharmacokinetics of metformin were associated with glucose-lowering effect of metformin. The aim of this study was to evaluate pharmacogenetic variation in SLC47A1 (rs2289669) and metformin response in type 2 diabetes patients. Seventy one patients with type 2 diabetes were included in the study. The genotypes were determined by Tetra-ARMS-PCR method. There was a significant association between the study polymorphism and the response to metformin treatment with the highest HbA1C reduction in AG genotype. In the dominant model for A allele (AA+AG vs GG), patients with A allele had highest HbA1C reduction in response to metformin.

Keywords: Diabetes; Pharmacogenetics; Polymorphism; SLC47A1.